nextcure.com (NXTC) - Utang marang Ekuitas

Lambang korporat lan logo NextCure Corporation (NXTC)

The price history of NextCure, Inc. (NXTC) demonstrates a total debt-to-equity ratio of 0.36. The company's quotes are minimally dependent on macroeconomics, as demand for oncology drugs remains stable. The business relies on expanding its antibody portfolio via the FIND IT system to identify partners. However, the current research stage does not provide economies of scale, triggering a proportional increase in R&D expenses.

NXTC - Rasio Total Utang marang Ekuitas NextCure ing rentang 04.07.2022 - 28.10.2026

Rincian metrik komprehensif lan analitis NextCure Corporation (NXTC)

- rega lan prakiraan konsensus rega:
Bagan rega NextCure|NXTC - Rata-rata rega prakiraan
- data kapitalisasi pasar:
Nilai pasar NextCure|NXTC - Nilai Bisnis
- data kapitalisasi buku:
Nilai Buku saben Saham NextCure|NXTC - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku nextcure.com|NXTC - Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas NextCure, Inc.|NXTC - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas NextCure, Inc.|NXTC - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku NextCure|NXTC - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan NextCure
Analisis dhasar perusahaan:NextCure (NXTC)
Barang utama NextCure, Inc.

This ratio determines the proportion of borrowed funds to equity assets, allowing for an assessment of financial autonomy and the risk of excessive corporate leverage. By analyzing the debt-to-equity level, an investor can judge the ability of NextCure, Inc. (NXTC) to ensure continuous funding for R&D projects and retain leading immunologists through a stable capital structure within the context of its scientific activities.

Analisis perusahaan pesaing

Utang marang Ekuitas IBRX (ImmunityBio)|Utang marang Modal IMCR|Utang marang Ekuitas Janux Pharma JANX|Rasio Utang marang Ekuitas Arcus Corp (RCUS)|Zymeworks Inc. - Total Utang marang Modal|tangotx.com - Rasio Total Utang marang Ekuitas|IOVA (Iovance Biotherapeutics, Inc.) - Utang marang Ekuitas|IMTX: Utang marang Modal|Xencor Corp (XNCR) - Utang marang Ekuitas|CMPX (Compass Therapeutics Corp) - Utang marang Ekuitas|Utang marang Ekuitas REPL (Replimune Group, Inc.)|Utang marang Modal lyell.com|IPHA: Total Utang marang Modal|Rasio Utang marang Modal pyxisoncology.com PYXS|CGEN: Rasio Total Utang marang Ekuitas|IOBT - Utang marang Modal|Rasio Total Utang marang Ekuitas Sutro Biopharma, Inc. (STRO)|INKT - Rasio Kabeh Utang marang Dana Pribadi|werewolftx.com - Total Utang marang Modal|IMMX (Immix Biopharma) - Koefisien Total Utang marang Modal|Utang marang Ekuitas ALXO|Rasio Total Utang marang Ekuitas CUE|Utang marang Ekuitas PDSB (PDS Biotechnology)|Rasio Total Utang marang Ekuitas sonnetbio.com SONN|Rasio Total Utang marang Ekuitas MAIA (MAIA Biotechnology, Inc.)|Liminatus Pharma Inc. - Total Utang marang Modal|Lava Tx (LVTX) - Utang marang Ekuitas|LPTX: Rasio Utang marang Ekuitas|Utang marang Ekuitas INTS|Utang marang Modal Sensei Biotherapeutics, Inc.|Theriva Biologics - Rasio Total Utang marang Ekuitas|Rasio Utang marang Modal Gritstone Bio (GRTS)|Rasio Total Utang marang Ekuitas Kineta Bio|Utang Agregat marang Modal NexImmune Corporation (NEXI)|Total Utang marang Modal Turnstone Biologics Corp.|Rasio Kabeh Utang marang Dana Pribadi vaccinex.com VCNX|HARP (Harpoon Therapeutics, Inc.) - Total Utang marang Modal